Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958123 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects
A Phase 1 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
NCT03958123 is a Phase 1 study that has completed, run by Tris Pharma. The registered enrollment target is 171 participants.
The verdict
NCT03958123, a Phase 1 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the effects of cebranopadol (GRT6005) on the electrical activity of the heart in healthy participants. The study consisted of a screening period within 21 days before the first dose of investigational medicinal product (IMP) (between Day -25 and Day -4) during which informed consent was obtained and the general suitability of the participants for the trial was assessed according to the inclusion/exclusion criteria. Participants were confined to the trial site from 4 days before first IMP dosing on Day 1 to 4 days after last IMP dosing on Day 30. During this period, multiple-doses of cebranopadol or matching placebo and a single-dose of moxifloxacin or matching placebo were administered. Moxifloxacin was used as a positive control. It has consistently shown that it has an effect on the heart rhythm. Continuous 12-lead ECGs were recorded at defined time points. Multiple blood and urine samples were drawn for pharmacokinetic evaluations and safety laboratory monitoring (hematology, chemistry, and urinalysis). Additional safety evaluations included recording of adverse events, vital signs (systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature, and weight), oxygen saturation, standard 12-lead ECG, Clinical Opiate Withdrawal Scale (COWS) assessment, and Columbia-Suicide Severity Rating Scale (C-SSRS) assessment. An End-of-Trial Visit was performed on Day 34, or within 7 days after the last pharmacokinetic sample on Day 34, or at early withdrawal.
Interventions
- DRUG 100 μg cebranopadol
- DRUG 200 μg cebranopadol
- DRUG 400 μg cebranopadol
- DRUG Placebo to cebranopadol encapsulated tablets
- DRUG 400 mg Moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2013-07-10 |
| Est. Completion | 2013-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03958123
The ClinicalTrials.gov registry entry for NCT03958123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 100 μg cebranopadol is the first listed.
NCT03958123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03958123 about?
NCT03958123 is a clinical study titled "Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects". The objective of this study was to evaluate the effects of cebranopadol (GRT6005) on the electrical activity of the heart in healthy participants. The study consisted of a screening period within 21 days before the first dose of investigational medicinal product (IMP) (between Day -25 and Day -4) d...
What is the current status of trial NCT03958123?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2013-07-10. Estimated completion is 2013-11-27.
What interventions are being tested in trial NCT03958123?
The interventions under investigation include: 100 μg cebranopadol (DRUG), 200 μg cebranopadol (DRUG), 400 μg cebranopadol (DRUG), Placebo to cebranopadol encapsulated tablets (DRUG), 400 mg Moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT03958123?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.